Pet IL-5/IL-5R Therapeutic Antibody Development

Creative Biolabs specializes in the development of therapeutic antibodies tailored to the unique immunological needs of companion animals. Our expertise spans every stage of antibody research, from discovery to preclinical evaluation, with a strong focus on novel immune targets such as IL-5 and IL-5R. By combining scientific precision with cutting-edge technologies, we enable the creation of innovative therapies designed to improve the health and quality of life of dogs and cats suffering from chronic and immune-mediated diseases.

Platforms in Therapeutic Antibody Discovery

We provide comprehensive R&D services through multiple discovery platforms designed to meet diverse client needs.

• Phage Display: Our species-specific antibody libraries allow us to identify and optimize lead molecules with high affinity and specificity for IL-5 or IL-5R. This platform enables rapid exploration of diverse candidates, minimizing development timelines.
• Single-B Cell Sorting: By isolating antigen-specific B cells, we can capture the natural antibody. This approach is particularly valuable for generating fully species-adapted antibodies suitable for downstream engineering and optimization.
• Hybridoma Technology: Hybridoma generation remains a reliable method for producing stable, high-yield monoclonal antibodies. We integrate hybridoma-derived leads with advanced engineering strategies to enhance therapeutic performance.

Comprehensive Antibody Development Services

Our capabilities extend beyond discovery, providing a full suite of services to advance IL-5/IL-5R therapeutic antibodies toward clinical readiness.

Antibody Characterization

Comprehensive profiling of binding kinetics, epitope mapping, and functional validation ensures candidate reliability.

Antibody Engineering

Structural optimization enhances stability, species compatibility, and pharmacological performance for veterinary applications.

Preclinical Evaluation

Rigorous in vitro and in vivo studies assess efficacy, safety, and tolerability in species-relevant models.

Antibody Development

From lead selection to scalable production, we provide seamless project execution with regulatory-ready documentation.

Discover How We Can Help - Request a Consultation

Why Focus on IL-5 / IL-5R?

IL-5 is a critical cytokine involved in eosinophil activation, survival, and recruitment, while IL-5R serves as its signaling receptor. Dysregulation of this pathway is linked to eosinophilic disorders, allergic inflammation, and asthma-like conditions in companion animals. In dogs, eosinophilic bronchopneumopathy is a notable example of IL-5–driven pathology, while in cats, eosinophilic granuloma complex and allergic airway disease present similar immunological challenges. By targeting IL-5 or IL-5R, therapeutic antibodies offer a promising strategy to reduce excessive eosinophil activity, alleviate inflammation, and improve long-term outcomes for affected pets.

Mechanism of Action

Therapeutic antibodies against IL-5 or IL-5R work by disrupting the signaling cascade responsible for eosinophil proliferation and survival. Anti-IL-5 antibodies neutralize the cytokine, preventing its interaction with the receptor, while anti-IL-5R antibodies directly block receptor activation. Both approaches reduce circulating and tissue-resident eosinophil counts, mitigating inflammation and tissue damage. In pets, this translates into reduced respiratory distress, improved skin health, and better management of chronic allergic conditions, providing a targeted alternative to corticosteroids and other non-specific treatments.

Fig 1. Role of the IL-5 axis in eosinophil-associated diseases and therapeutic interventions.¹

Our Advantages

• Species-Specific Expertise: Our canine and feline-focused platforms ensure antibody candidates are tailored to the unique immunological profiles of pets, reducing immunogenicity risks.
• Integrated Workflow: From discovery to preclinical testing, all services are managed under one roof, ensuring efficiency and seamless project progression.
• Advanced Technologies: We leverage cutting-edge methods, including next-generation sequencing and structural modeling, to accelerate candidate optimization.
• Collaborative Approach: We prioritize transparency and communication, tailoring each project to client needs and fostering long-term research partnerships.

Partner with Creative Biolabs

Creative Biolabs is committed to advancing the frontier of veterinary therapeutics through innovative antibody development. Our IL-5 and IL-5R programs exemplify how targeted biologics can address unmet medical needs in dogs and cats, offering safer and more effective alternatives for chronic inflammatory and allergic diseases. Whether you seek early discovery support, preclinical evaluation, or complete development solutions, we are prepared to collaborate closely to bring your vision to reality. Contact us today to explore partnership opportunities and accelerate your therapeutic pipeline.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Ou, Weiying et al. "Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy." Frontiers in immunology vol. 17 1817893. 10 Apr. 2026. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2026.1817893